Regeneron Pharmaceuticals IncREGN
▲ PositiveTechnologyrelevance
Regeneron's Pozelimab plus Cemdisiran is highlighted as the emerging PNH therapy expected to generate the highest revenue, with Phase III results anticipated in Q4 2026/Q1 2027.
Impact on assets 4
Biotech & Genomic Medicine
Regeneron Pharmaceuticals Inc
Omeros CorporationOMER
▲ PositiveCapitalrelevance
Novo Nordisk gained exclusive worldwide rights to zaltenibart through an asset purchase and license agreement with Omeros announced in November 2025.
Jasper Therapeutics IncJSPR
Mentioned
Longevity & Life Extension
Novo Nordisk A/SNVO
▲ PositiveTechnologyrelevance
Novo Nordisk's Zaltenibart is highlighted as a key emerging PNH therapy, showing strong Phase II efficacy and expected to be the second-highest revenue generator.
Theme Impact 1
Off-coverage companies 2
NovelMed TherapeuticsPrivate▲ Positive
Technologyrelevance
NovelMed's Ruxoprubart (NM8074) and NM5072 are among the five emerging therapies poised to reshape the PNH market.
DelveInsightPrivate± Mixed
relevance
Related news
United States▲
Wells Fargo Starts Design Therapeutics at Overweight on Friedreich Ataxia Program
Wells Fargo initiated coverage of Design Therapeutics with an overweight rating, citing the company's Friedreich ataxia candidate DT-216P2 as having potentially best-in-disease functional improvement based on results from the RESTORE-FA study released in May. The bank set a $26 price target, implying roughly 112% upside based on the October 1 close. Analyst TianQi Hang wrote that the May update showed pharmacokinetics look good, and that blood-FXN protein, muscle-mRNA data, plus an early mFARS signal further de-risk the platform. Hang estimates that the blood FXN protein increase seen after 6 weeks can translate to at least a 2-point mFARS change, and said that if the drug kinetics sustain for 12 weeks, which he believes they will, DT-216P2 could deliver best-in-disease functional benefits. He assigns DT-216P2 a 60% probability of success, with peak sales of approximately $600M in the US and approximately $900M outside it. If approved, DT-216P2 would compete against Biogen's Skyclarys, also known as omaveloxolone, and Hang sees it gaining a peak share of the FA treatment market of 30% in the US and 20% ex-US.
About megatrends
Biotech & Genomic Medicine › Rare Disease ▲Competition
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Competition
Biotech & Genomic Medicine › RNAi / Antisense Oligonucleotides Competition
Biotech & Genomic Medicine › RNA Therapeutics ▲Competition
United States
European Union
DenmarkAgios Bets on Mitapivat Expansion as Sickle Cell Decision Looms
Agios Pharmaceuticals is leaning heavily on its lead therapy mitapivat for near- to medium-term growth after pipeline setbacks and rising competition in sickle cell disease. Pyrukynd and Aqvesme together generated $44.7 million in worldwide net revenues in the second quarter of 2026, up 259.3% year over year, following the January 2026 U.S. launch of Aqvesme for adults with alpha- or beta-thalassemia. Aqvesme recorded 442 cumulative prescriptions from REMS-certified U.S. physicians as of June 30, 2026, up from 242 at the end of the first quarter, while the European Commission approved Pyrukynd for thalassemia in May 2026. Agios has submitted a supplemental new drug application for mitapivat in sickle cell disease under the accelerated approval pathway, and the FDA has granted priority review with a final decision expected by Nov. 1, 2026. The company discontinued its next-generation PK activator tebapivat in mid-2026 after setbacks in lower-risk myelodysplastic syndromes and sickle cell disease, and it faces competition from Novo Nordisk's etavopivat, which Novo Nordisk plans to file for approval in the fourth quarter of 2026, as well as from Bristol Myers Squibb's Reblozyl and Novartis' Adakveo.
About megatrends
Biotech & Genomic Medicine › Rare Disease Competition
AGIO · Demand · Positive Pyrukynd and Aqvesme Q2 2026 net revenues rose 259.3% YoY with 442 cumulative Aqvesme prescriptions, showing strong product adoption.
AGIO · Regulation · Positive FDA granted priority review to Agios' sNDA for mitapivat in sickle cell disease with a decision expected by Nov. 1, 2026.
NVO · Competition · Neutral Novo Nordisk's etavopivat is cited as a rival therapy Agios faces, with a planned Q4 2026 filing, but no new Novo-specific news.
United Statesimpact 4
United Therapeutics Jumps 12.5% After Delaware Court Rules Liquidia's Yutrepia Infringes Patent
United Therapeutics shares ended the last trading session 12.5% higher at $541.89 after a Delaware court ruled that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD. The ruling could lead to restrictions on Yutrepia's PH-ILD use, potentially reducing competition for United Therapeutics' Tyvaso and Tyvaso DPI products, and the company could further benefit from potential monetary damages related to Liquidia's past infringement, although the final remedies remain pending. The drugmaker is expected to post quarterly earnings of $6.38 per share in its upcoming report, a year-over-year change of -10.9%, on revenues of $792.64 million, down 0.9% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 1.4% lower over the last 30 days, and the stock currently carries a Zacks Rank #3 (Hold).
About megatrends
Biotech & Genomic Medicine › Rare Disease Competition
LQDA · Regulation · Negative Delaware court ruled Liquidia's Yutrepia infringes United Therapeutics' patent, potentially restricting Yutrepia's PH-ILD use.
UTHR · Regulation · Positive Court ruling that Liquidia's Yutrepia infringes UTHR's patent could reduce competition for Tyvaso and lead to monetary damages.